Strategic partnerships Tapemark’s history of collaborations with industry leaders like LTS Lohmann Therapie-Systeme AG and 10x Technology LLC signals strong open channels for co-development and manufacturing partnerships in transdermal and oral thin film delivery. This presents opportunities to approach potential OEMs and CDMOs looking for integrated formulation, coating, and packaging capabilities.

Full-service capabilities With end-to-end offerings from formulation to primary and secondary packaging and kitting, Tapemark can be positioned as a one-stop partner for companies seeking streamlined NDA, ANDA, or 505(b)(2) filings and faster time-to-market for transdermal and oral thin film products.

FDA approvals expertise Tapemark emphasizes deep experience guiding products through FDA processes and successful NDA/ANDA/505(b)(2) approvals, including Schedule I substances. This can be a selling point for sponsors needing regulatory-aligned manufacturing and documentation support to de-risk approval timelines.

Scale and quality Operating a 150,000-square-foot facility with a focus on cutting-edge equipment and qualified personnel positions Tapemark as capable of handling mid- to large-scale production while maintaining quality and compliance, ideal for clients planning scalable launches.

Market positioning Tapemark’s specialization in transdermal and oral thin film technologies, combined with private ownership and campus-style facilities, suggests a niche competitive edge for firms seeking innovative drug-delivery solutions and efficient collaboration in the CDMO landscape.